睿知中国医院研究地图
候选清单

即将招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由复旦大学附属中山医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07919717,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Subjects must have intrahepatic recurrence confirmed by imaging (contrast-enhanced CT or MRI) occurring 3 months to 2 years after initial liver resection.

    入选标准第 7 条

  3. Presence of concomitant malignancy requiring treatment (at screening) or history of active prior malignancy within 2 years prior to enrollment. Note: Subjects with a history of prior malignancy are eligible if treatment was completed >= 2 years ago and there is no evidence of disease. Additionally, subjects with a history of prior early-stage basal/squamous cell skin cancer or non-invasive/in situ carcinoma are eligible if they received targeted therapy at any time.

    排除标准第 36 条

  4. Subjects should, as much as possible, provide tumor tissue specimens from the initial surgical resection of HCC (1 formalin-fixed paraffin-embedded [FFPE] tissue block or 20 unstained tumor tissue slides) during the screening period.

    入选标准第 6 条

    HBV infection: If HBsAg positive, HBV-DNA must be measured, and HBV-DNA must be < 2000 IU/mL or < 10\^4 copies/mL. Subjects must have received at least 1 week of anti-HBV therapy prior to enrollment and be willing to continue antiviral therapy throughout the study.

    入选标准第 38 条

    Recurrence within less than 3 months after surgery.

    排除标准第 4 条

    Prior systemic antitumor therapy for recurrent HCC, including but not limited to immunotherapy (PD-1, PD-L1, CTLA-4 antibodies, or bispecific/combination antibodies).

    排除标准第 6 条

    History of any CTCAE Grade >= 3 hemorrhagic events within 8 weeks prior to enrollment, or currently receiving thrombolytic therapy.

    排除标准第 27 条

    Systemic treatment with corticosteroids (> 10 mg/day prednisone or equivalent) or other immunosuppressive agents within 14 days prior to study drug administration.

    排除标准第 28 条

  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0.

    入选标准第 18 条

  6. Absolute neutrophil count (ANC) >= 1.5 x 10\^9/L

    入选标准第 22 条

    Platelet count (PLT) >= 75 x 10\^9/L

    入选标准第 23 条

    Hemoglobin (HGB) >= 9.0 g/dL

    入选标准第 24 条

    Serum total bilirubin (TBIL) <= 2 x upper limit of normal (ULN)

    入选标准第 26 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 5 x ULN

    入选标准第 27 条

    Alkaline phosphatase (ALP) <= 5 x ULN

    入选标准第 29 条

    Serum creatinine (Cr) <= 1.5 x ULN or creatinine clearance (CCr) >= 50 mL/min (calculated using the Cockcroft-Gault formula)

    入选标准第 32 条

    International Normalized Ratio (INR) and activated partial thromboplastin time (APTT) <= 1.5 x ULN

    入选标准第 36 条

  7. Subjects must have at least one previously untreated lesion that is measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

    入选标准第 15 条

    The lesion must be accurately measured in at least one dimension using contrast-enhanced spiral computed tomography (CT) or contrast-enhanced dynamic magnetic resonance imaging (MRI), with a result >= 10 mm. Note: for malignant lymph nodes, the short axis must be >= 15 mm.

    入选标准第 16 条

  8. Known human immunodeficiency virus (HIV)-positive history or known AIDS history, or currently receiving systemic corticosteroid therapy. Note: HIV testing must be performed at a locally authorized institution.

    排除标准第 9 条

  9. Women of childbearing potential (WOCBP) must have a serum pregnancy test within 7 days prior to enrollment, with a negative result (minimum sensitivity 25 IU/L or equivalent HCG units).

    入选标准第 40 条

    Female subjects must not be breastfeeding.

    入选标准第 41 条

    Female subjects of reproductive potential and their partners must agree to use effective contraception during the study and for at least 6 months after the last dose. WOCBP must also agree not to donate oocytes during this period.

    入选标准第 42 条

    Pregnant or breastfeeding women of childbearing potential (WOCBP).

    排除标准第 40 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07919717,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The subject or their legally authorized representative must sign a written informed consent form (ICF) approved by the IRB/IEC, with the date indicated, prior to undergoing any study-related procedures.
  2. Subjects must be willing and able to comply with the scheduled visits, treatment regimen, laboratory assessments, and other study requirements.
  3. Male and female subjects aged >= 18 and <= 75 years.
  4. Expected life expectancy of >= 3 months.
  5. Subjects must have histologically, cytologically, or clinically confirmed HCC.
  6. Subjects should, as much as possible, provide tumor tissue specimens from the initial surgical resection of HCC (1 formalin-fixed paraffin-embedded [FFPE] tissue block or 20 unstained tumor tissue slides) during the screening period.
  7. Subjects must have intrahepatic recurrence confirmed by imaging (contrast-enhanced CT or MRI) occurring 3 months to 2 years after initial liver resection.
  8. Subjects must be assessed by the investigator as eligible for repeat hepatic resection, in accordance with the Chinese Expert Consensus on Prevention and Treatment of Postoperative Recurrence of Hepatocellular Carcinoma (2020 edition):
  9. Subjects in generally good condition.
  10. Liver function Child-Pugh class A, with none or only mild portal hypertension.
  11. No severe underlying diseases of major organs such as heart, lung, or kidney.
  12. Lesion(s) are either solitary or multiple (<= 3) with the maximum diameter of a single lesion <= 3 cm, and technically resectable; for multiple lesions, enrollment is allowed only after investigator assessment of the remaining liver volume and surgical safety margins.
  13. Expected residual liver volume after repeat hepatectomy sufficient to maintain adequate liver function.
  14. No major vascular invasion or extrahepatic distant metastasis.
  15. Subjects must have at least one previously untreated lesion that is measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
  16. The lesion must be accurately measured in at least one dimension using contrast-enhanced spiral computed tomography (CT) or contrast-enhanced dynamic magnetic resonance imaging (MRI), with a result >= 10 mm. Note: for malignant lymph nodes, the short axis must be >= 15 mm.
  17. The lesion must not have been previously treated with surgery, radiotherapy, and/or local regional therapy (e.g., RFA, PEI or PAI, cryoablation, HIFU, TACE, TAE, etc.).
  18. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0.
  19. Subjects must not have received prior systemic immune checkpoint inhibitor therapy.
  20. Subjects must have adequate organ and bone marrow function. Screening laboratory values must meet the following criteria and must be obtained within 7 days prior to enrollment (administration of any blood products, growth factors, albumin, or other corrective treatments is not permitted within 14 days prior to obtaining the laboratory assessments):
  21. Adequate hematologic function:
  22. Absolute neutrophil count (ANC) >= 1.5 x 10\^9/L
  23. Platelet count (PLT) >= 75 x 10\^9/L
  24. Hemoglobin (HGB) >= 9.0 g/dL
  25. Adequate hepatic function:
  26. Serum total bilirubin (TBIL) <= 2 x upper limit of normal (ULN)
  27. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 5 x ULN
  28. Serum albumin >= 28 g/L
  29. Alkaline phosphatase (ALP) <= 5 x ULN
  30. In the Child-Pugh classification, only one of the 2 parameters, albumin or bilirubin, may be scored as 2 points.
  31. Adequate renal function:
  32. Serum creatinine (Cr) <= 1.5 x ULN or creatinine clearance (CCr) >= 50 mL/min (calculated using the Cockcroft-Gault formula)
  33. Urinalysis showing protein < 2+
  34. For subjects with baseline urinalysis showing protein >= 2+, a 24-hour urine collection must be performed, with 24-hour urine protein < 1g
  35. Adequate coagulation function:
  36. International Normalized Ratio (INR) and activated partial thromboplastin time (APTT) <= 1.5 x ULN
  37. Subjects with HBV or HCV infection must meet the following criteria:
  38. HBV infection: If HBsAg positive, HBV-DNA must be measured, and HBV-DNA must be < 2000 IU/mL or < 10\^4 copies/mL. Subjects must have received at least 1 week of anti-HBV therapy prior to enrollment and be willing to continue antiviral therapy throughout the study.
  39. HCV infection: HCV-RNA positive subjects (RNA < 10\^3 copies/mL) must receive antiviral therapy according to treatment guidelines.
  40. Women of childbearing potential (WOCBP) must have a serum pregnancy test within 7 days prior to enrollment, with a negative result (minimum sensitivity 25 IU/L or equivalent HCG units).
  41. Female subjects must not be breastfeeding.
  42. Female subjects of reproductive potential and their partners must agree to use effective contraception during the study and for at least 6 months after the last dose. WOCBP must also agree not to donate oocytes during this period.

排除标准:Exclusion Criteria:

  1. Histologically confirmed fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma-HCC.
  2. Prior liver transplantation.
  3. Presence of extrahepatic metastases or unresectable lesions confirmed by imaging within 1 month prior to enrollment.
  4. Recurrence within less than 3 months after surgery.
  5. Lesions assessed as unresectable.
  6. Prior systemic antitumor therapy for recurrent HCC, including but not limited to immunotherapy (PD-1, PD-L1, CTLA-4 antibodies, or bispecific/combination antibodies).
  7. Prior local therapy after recurrence, including transarterial chemoembolization (TACE), ablation (radiofrequency ablation, microwave ablation, cryoablation, etc.), or radiotherapy.
  8. Active co-infection with hepatitis B and hepatitis C or hepatitis B and hepatitis D that is not effectively controlled.
  9. Known human immunodeficiency virus (HIV)-positive history or known AIDS history, or currently receiving systemic corticosteroid therapy. Note: HIV testing must be performed at a locally authorized institution.
  10. Active bacterial, fungal, or viral infection requiring systemic therapy within 1 week prior to enrollment.
  11. History of hepatic encephalopathy (>= Grade 2) within 12 months prior to enrollment.
  12. Clinically significant ascites, defined as:
  13. Ascites previously requiring treatment and ongoing prophylaxis, or
  14. Ascites currently requiring treatment.
  15. Presence of portal hypertension with a history of bleeding from esophageal or gastric varices within 6 months prior to enrollment.
  16. Uncontrolled cardiac clinical symptoms or diseases, including but not limited to:
  17. Uncontrolled hypertension despite optimal therapy, defined as systolic blood pressure > 150 mmHg or diastolic blood pressure > 90 mmHg.
  18. History of congestive heart failure greater than New York Heart Association (NYHA) class II.
  19. Active coronary artery disease, unstable or newly diagnosed angina, or myocardial infarction within 6 months prior to screening.
  20. Arrhythmias requiring antiarrhythmic therapy other than beta-blockers or digoxin at screening.
  21. Cardiac valvular disease graded > Grade 2 according to CTCAE.
  22. QTc interval (Fridericia formula) > 480 ms on 2 consecutive ECGs.
  23. Symptomatic or potentially interfering interstitial lung disease that may affect the detection or management of drug-related pulmonary toxicity.
  24. History of gastrointestinal or non-gastrointestinal fistula or gastrointestinal perforation.
  25. History of non-healing wounds or skin ulcers within 3 months prior to enrollment.
  26. History of thrombotic or embolic events (excluding HCC tumor thrombus) within 6 months prior to enrollment, such as cerebrovascular accidents (including transient ischemic attacks) or pulmonary embolism.
  27. History of any CTCAE Grade >= 3 hemorrhagic events within 8 weeks prior to enrollment, or currently receiving thrombolytic therapy.
  28. Systemic treatment with corticosteroids (> 10 mg/day prednisone or equivalent) or other immunosuppressive agents within 14 days prior to study drug administration.
  29. Immunological contraindications or concurrent severe autoimmune diseases where the investigator considers immune checkpoint inhibitor therapy to carry excessive risk, including but not limited to:
  30. Active severe autoimmune diseases (e.g., systemic lupus erythematosus, Sjogren's syndrome, myasthenia gravis, ulcerative colitis, Crohn's disease, refractory psoriasis, etc.) requiring medium- to high-dose immunosuppressive therapy for maintenance.
  31. Confirmed severe combined immunodeficiency, acquired immunodeficiency syndrome (AIDS), or immunodeficiency states such as critically low CD4+ T-cell counts.
  32. Recent (e.g., <= 14 days) or ongoing use of high-dose systemic corticosteroids (> 10 mg/day prednisone equivalent) or other drugs affecting immune function (short-term use for irAE management or perioperative period is not included).
  33. Requirement for ongoing immunosuppressive therapy due to organ transplantation.
  34. Investigator's assessment based on medical history or current condition indicates other high-risk immunologic abnormalities that make the subject unsuitable for immune checkpoint inhibitor therapy.
  35. Known hypersensitivity to Nivolumab, Ipilimumab, any of their excipients, or history of severe hypersensitivity reactions to other monoclonal antibodies.
  36. Presence of concomitant malignancy requiring treatment (at screening) or history of active prior malignancy within 2 years prior to enrollment. Note: Subjects with a history of prior malignancy are eligible if treatment was completed >= 2 years ago and there is no evidence of disease. Additionally, subjects with a history of prior early-stage basal/squamous cell skin cancer or non-invasive/in situ carcinoma are eligible if they received targeted therapy at any time.
  37. Any serious or uncontrolled medical condition that, in the investigator's opinion, may increase the risk of participation, compromise the subject's ability to receive study treatment, or interfere with the interpretation of study results.
  38. History of major surgical procedures, open biopsies, or significant trauma within 4 weeks prior to enrollment, or minor surgical procedures (e.g., core needle biopsy) within 1 week prior to enrollment.
  39. Subjects with a history of life-threatening toxicities related to prior systemic anticancer therapy, except for those unlikely to recur after standard-of-care management.
  40. Pregnant or breastfeeding women of childbearing potential (WOCBP).

引自 ClinicalTrials.gov, NCT07919717, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07919717,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07919717